Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. We believe that a healthy economy, environment and society are fundamental to long-term value creation. This is why we manage our business in accordance with the Triple Bottom Line business principle and consider the financial, environmental and social impact of our business decisions. The strategic commitment to corporate sustainability has brought the company onto centre stage as a leading player in today's business environment, recognised for its integrated reporting, stakeholder engagement and consistently high sustainability performance.
Today Novo Nordisk published its 2013 Annual Report detailing the company’s social, environmental and financial results for 2013. The report highlights the company’s progression towards long-term targets during a year of challenges...
Last week, the Corporate Knights Global 100 Most Sustainable Companies index was released at the World Economic Forum in Davos. Although down two places from last year in the overall ranking. Novo Nordisk was recognised for its strong and consistent performance throughout the past decade.
Novo Nordisk employees in Mexico are the winners of the 2013 TakeAction award recognising their efforts to provide food, basic goods and insulin to people affected by two hurricanes which left thousands homeless and large areas without electricity, food or clean water.
“The tremendous effo...
The recent estimate from the International Diabetes Federation (IDF) Diabetes Atlas shows that globally 382 million people have diabetes, a figure that is equal to the combined population of the United States and United Kingdom. People living with diabetes in low- and middle-income countries make...
Yesterday, Novo Nordisk received top placement in the Dow Jones Sustainability Index (DJSI) and the Carbon Disclosure Project (CDP), two of the most influential rankings of sustainability performance and disclosure by private companies. The company achieved 85 points in the DJSI compared to 86 po...
On 3 September, Novo Nordisk and the Indonesian Ministry of Health launched a joint platform to guide efforts to address the rising prevalence of diabetes and its associated costs. The platform is built on the findings from Novo Nordisk’s
Today, Novo Nordisk publishes its second issue of the company’s digital sustainability magazine – The TBL Quarterly. The content in the new issue, Responsible Production, explores the successes and challenges of managing the company’s environmental impact at its global insulin p...
Today, Novo Nordisk publishes the first issue of the company’s new digital sustainability magazine – The TBL Quarterly. The Q1 issue shows how Novo Nordisk is changing diabetes in Vietnam, Malaysia and Indonesia, from prevention to educating healthcare professionals on how to diagnose an...
Novo Nordisk’s eighth annual integrated report, now online, reports on the company’s very positive financial, social and environmental performance for 2011. Download the Annual Report 2011 at
/PRNewswire/ - Novo Nordisk (NYSE: NVO), the world leader in diabetes care, has been ranked 43rd in FORTUNE magazine's 2012 "100 Best Companies to Work For" list. Reflecting the passion of Novo Nordisk's employees, the company has been highlighted on the list for four consecutive years.